APIs and Excipients

GSK and Alector Collaborate on Neurodegenerative Disease mAb Candidates

July 09, 2021

GlaxoSmithKline and Alector have partnered to co-develop two mAbs for a range of neurodegenerative diseases, including Parkinson’s and Alzheimer’s disease.

Complex Biomolecules Require Analytical Evolution

July 03, 2021

The ever-increasing complexity of biotherapeutic molecules presents unique analytical challenges for developers.

Meeting Future Analytical Requirements for Novel Biotherapeutics

July 03, 2021

The future pipeline of complex novel biotherapeutics will require new approaches to analytical assessment.

Subunit Vaccines and the Fight Against COVID-19

July 03, 2021

Advances in technology are accelerating the development and manufacture of subunit vaccines, an established class of vaccines.

Formulating Tablets Layer by Layer

July 03, 2021

Bi-layer tablets are an under-utilized option that can be employed to help reduce treatment burden, but their formulation is more complex than for conventional monolayer products.

Selexis and KBI Biopharma Partner with Immatics to Advance T-Cell Bispecific Program

July 01, 2021

Selexis and KBI Biopharma will use integrated services to advance Immatics’ TCR bispecifics drug development program to the IND stage.

Corbus Pharmaceuticals Expands Pipeline with Two New mAbs

June 30, 2021

Corbus Pharmaceuticals has licensed two integrin-targeting mAbs, expanding its therapeutics pipeline into inflammatory, fibrotic, and metabolic diseases as well as cancer.

AbbVie to Acquire TeneoOne and Lead Asset for Multiple Myeloma Treatment

June 25, 2021

AbbVie has exercised its right to acquire TeneoOne, along with its lead immunotherapeutic asset for the potential treatment of multiple myeloma.

Lilly's Investigational Alzheimer's Therapeutic Gets Breakthrough Therapy Designation

June 25, 2021

FDA has granted breakthrough therapy designation to donanemab, Eli Lilly and Co.’s investigational antibody treatment for Alzheimer’s disease.

SelectImmune and Lonza to Develop Immunotherapeutic Drug Candidate

June 24, 2021

The companies have entered into an agreement to develop processes for a novel immunotherapy protein.